Skip to main
PYPD
PYPD logo

PolyPid (PYPD) Stock Forecast & Price Target

PolyPid (PYPD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PolyPid Ltd has demonstrated significant progress in advancing its clinical programs, particularly with D-PLEX100, which has shown positive efficacy-risk characteristics in a Phase 3 study aimed at preventing surgical site infections. The recent reduction in net loss per share, attributed to a substantial increase in share count, indicates improved financial stability as the company prepares for a critical pre-NDA meeting with the FDA planned for December. Furthermore, a strategic collaboration with AdvanzPharma in the EU highlights the company's commitment to leveraging partnerships that can enhance market potential and investor confidence as it approaches potential product approvals.

Bears say

PolyPid Ltd faces significant risks regarding the efficacy of its product candidates, as the potential failure to deliver statistically significant results in clinical studies poses a substantial threat to the company's valuation. Additionally, even with successful clinical outcomes, there are uncertainties surrounding the approval process by regulatory agencies, which could further diminish the perceived value of its products. Compounded by the complexity surrounding patent protections, which may lead to revenue erosion starting in 2036, these factors contribute to a negative outlook on PolyPid's stock.

PolyPid (PYPD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PolyPid (PYPD) Forecast

Analysts have given PolyPid (PYPD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, PolyPid (PYPD) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PolyPid (PYPD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.